BR9909322A - Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz - Google Patents

Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz

Info

Publication number
BR9909322A
BR9909322A BR9909322-7A BR9909322A BR9909322A BR 9909322 A BR9909322 A BR 9909322A BR 9909322 A BR9909322 A BR 9909322A BR 9909322 A BR9909322 A BR 9909322A
Authority
BR
Brazil
Prior art keywords
nitrogen
heterocyclylalkyl
aralkyl
alkyl
heteroarylalkyl
Prior art date
Application number
BR9909322-7A
Other languages
English (en)
Inventor
Paivi Jaana Kukkola
Leslie Anne Robinson
Junichi Sakaki
Motowo Nakajima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9909322A publication Critical patent/BR9909322A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE SULFONILAMINO QUE INIBEM METALOPROTEINASES DE DEGRADAçãO DE MATRIZ"<D>. Compostos de fórmula I na qual W é -OH ou -NHOH; X é a) um radical heterocíclico não-substituído ou substituído, selecionado do grupo consistindo em pirrolidinila, pirrolila, pirazolila, oxetanila, pirazolinila, imidazolinila, imidazolidinila, oxazolila, oxazolidinila, isoxazolinila, isoxazolila, tiazolila, tiadiazolila, tiazolidinila, isotiazolila, isotiazolidinila, furila, tetrahidrofurila, oxadiazolila, piperidinila, piperazinila, 2-oxopiperazinila, 2-oxopiperidinila, 2-oxopirrolodinila, 2-oxoazepinila, azepinila, 4-piperidinila, piridila, pirazinila, piridazinila, tetrahidropiranila, morfolinila, tiamorfolinila, sulfóxido de tiamorfolinila, sulfona de tiamorfolinila, 1,3-dioxolano, tetrahidro-1,1-dioxotienila, benzotiazolila, benzoxazolila, quinuclidinila, quinolinila, tetrahidroisoquinolinila, isoquinolinila, benzimidazolila, benzopiranila, idolizinila, benzofurila, cromonila, cumarinila, benzopiranila, cinolinila, quinoxalinila, indazolila, pirrolopiridila, furopiridinila, dihidrobenzoisotiazolila, dihidroquinazozolinila, tetrahidroquinazolinil e sistemas de anel tricíclico de 10 a 15 membros, que têm pelo menos um heteroátomo em pelo menos um anel contendo átomo de carbono, no qual cada anel do radical heterocíclico contendo um heteroátomo pode ter 1, 2 ou 3 heteroátomos selecionados dos átomos de nitrogênio, átomos de oxigênio e átomos de súrfur; com a condição de que quando X é um radical heterocíclico contendo nitrogênio, o radical heterocíclico é ligado à porção de (CH~ 2~)~ m~ por um nitrogênio de anel e a condição de que os heteroátomos de nitrogênio e enxofre do radical heterocíclico podem também ser oxidizados; b) -NR~ 1~SO~ 2~R~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclialquila, aralquila ou heteroarilalquila e R2 é hidrogênio, alquila, heterociclilalquila, aralquila, heteroarilalquila, arila ou heteroarila; c) heterociclialquiltio; d) -CONR~ 2~R~ 3~, no qual R~ 2~ e R~ 3~ tomados juntos com o átomo de nitrogênio ao qual eles são ligados formam um anel de 5 a 7 membros, que pode opcionalmente conter outro heteroátomo selecionado de oxigênio, nitrogênio e enxofre; ou e) -NR~ 1~COR~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclilalquila, aralquila ou heteroarilalquila e R~ 2~ é hidrogênio, heterociclilalquila, aralquila, heteroarilalquila ou arila; Y é carbono, nitrogênio, oxigênio ou enxofre, contanto que quando Y é carbono, n é 2; Z é alquila, arila, alcóxi, arilóxi, aralcoxiarila, aralcoxiheteroarila, heteroarila, heterociclila, heteroarilóxi, -CONR~ 2~R~ 3~, -NR~ 1~COR~ 2~, -NR~ 1~CONR~ 2~R~ 3~, -OCONR~ 2~R~ 3~, -NR~ 1~COOR~ 4~, ou -SO~ 2~R~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclilalquila, aralquila ou heteroarilalquila e R~ 2~ e R~ 3~ são independentemente hidrogênio, alquila, heterociclilalquila, aralquila, heteroarilalquila, arila ou heteroarila; ou R~ 2~ e R~ 3~ tomados juntos com o átomo de nitrogênio ao qual eles são ligados formam um anel de 5 a 7 membros, que pode opcionalmente conter outro heteroátomo selecionado de oxigênio, nitrogênio e enxofre; R~ 4~ é alquila, heterociclilalquila, aralquila, arila ou heteroarila; m representa um número inteiro de um a seis; e n representa o número inteiro de um ou dois; e sal farmaceuticamente aceitável destes; composições farmacêuticas compreendendo os referidos compostos e processos para sua preparação; um método de inibição de metaloproteinases de degradação de matriz em mamíferos empregando tais compostos e o uso destes derivados como medicamento. Os compostos de fórmula I são inibidores de metaloproteinases de degradação de matriz e são úteis para o tratamento de condições relacionadas com eles.
BR9909322-7A 1998-02-04 1999-02-02 Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz BR9909322A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1881998A 1998-02-04 1998-02-04
PCT/EP1999/000646 WO1999042443A1 (en) 1998-02-04 1999-02-02 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Publications (1)

Publication Number Publication Date
BR9909322A true BR9909322A (pt) 2000-12-05

Family

ID=21789936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909322-7A BR9909322A (pt) 1998-02-04 1999-02-02 Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz

Country Status (18)

Country Link
US (1) US6277987B1 (pt)
EP (2) EP1918278A1 (pt)
JP (1) JP4750272B2 (pt)
KR (1) KR20010040698A (pt)
CN (1) CN1195735C (pt)
AU (1) AU747911B2 (pt)
BR (1) BR9909322A (pt)
CA (1) CA2318145C (pt)
HU (1) HUP0101176A3 (pt)
ID (1) ID24957A (pt)
IL (1) IL137465A0 (pt)
NO (1) NO317977B1 (pt)
NZ (1) NZ505968A (pt)
PL (1) PL342009A1 (pt)
RU (1) RU2208609C2 (pt)
SK (1) SK11692000A3 (pt)
TR (1) TR200002224T2 (pt)
WO (1) WO1999042443A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069110A4 (en) * 1998-04-03 2004-09-01 Sankyo Co SULFONAMIDE DERIVATIVES
PL350452A1 (en) 1999-03-03 2002-12-16 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
HUP0202199A2 (en) * 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
WO2001023363A1 (fr) * 1999-09-29 2001-04-05 Sankyo Company, Limited Derives de sulfonamide
IL151125A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
SK13352002A3 (sk) * 2000-03-21 2003-05-02 The Procter & Gamble Company Metaloproteázové inhibítory s vedľajším heterocyklickým reťazcom
AU2001248701A1 (en) * 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE60233261D1 (de) * 2001-12-14 2009-09-17 Exelixis Inc Inhibitoren von humanem adam-10
AU2003221160A1 (en) * 2002-03-27 2003-10-08 Shionogi And Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
KR100701811B1 (ko) * 2002-05-29 2007-04-02 머크 앤드 캄파니 인코포레이티드 탄저병의 치료 및 치사 인자의 억제에 유용한 화합물
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CN1950354A (zh) 2004-05-11 2007-04-18 默克公司 N－磺酰化－氨基酸衍生物的制备方法
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20100247512A1 (en) * 2006-03-31 2010-09-30 The Regents Of The University Of Michigan Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP1972617A1 (en) * 2007-03-19 2008-09-24 Bracco Imaging, S.P.A. Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2009118292A1 (en) * 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02642B (me) * 2008-12-05 2017-06-20 Abbvie Inc Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
ITTO20090648A1 (it) * 2009-08-19 2011-02-20 Istituto Naz Per La Ricerca Sul Cancro Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc)
US9023318B2 (en) 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1493665A1 (de) 1964-07-16 1969-02-06 Hoechst Ag Verfahren zur Spaltung von aromatischen Carbonsaeureamiden
EP1002556A3 (en) 1992-05-01 2001-01-10 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US6022898A (en) 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
DK0874836T3 (da) 1995-11-17 2003-02-10 Warner Lambert Co Sulfonamidinhibitorer af matrix metalloproteinaser
SI0874830T1 (en) 1995-12-08 2003-08-31 Agouron Pharmaceuticals, Inc. A metalloproteinase inhibitor, a pharmaceutical composition containing it and the pharmaceutical use and method useful for the preparation thereof
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
DE69716934T2 (de) 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
AU731319B2 (en) 1996-08-28 2001-03-29 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors
BR9712792A (pt) 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
BR9712085A (pt) 1996-08-28 2000-10-24 Procter & Gamble Inibidores de metaloprotease heterocìclicos
TR199900429T2 (xx) 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
BR9713465A (pt) 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
ES2212142T3 (es) * 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
JP2001509810A (ja) * 1997-01-17 2001-07-24 ファルマシア・アンド・アップジョン・カンパニー Ｍｍｐインヒビターとしてのビス−スルホンアミドヒドロキサム酸
BR9809062A (pt) 1997-04-01 2000-08-01 Agouron Pharmaceuticlas Inc Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1998050348A1 (en) 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719585A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Substituierte Diaminocarbonsäuren
ES2165640T3 (es) * 1997-05-09 2002-03-16 Hoechst Ag Acidos diaminocarboxilicos sustituidos.
DE19719428A1 (de) 1997-05-12 1998-11-19 Hoechst Ag Substituierte Diaminocarbonsäuren
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
WO1999004780A1 (fr) 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
WO1999006340A2 (en) * 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors

Also Published As

Publication number Publication date
JP4750272B2 (ja) 2011-08-17
SK11692000A3 (sk) 2001-02-12
CN1195735C (zh) 2005-04-06
CN1290250A (zh) 2001-04-04
AU747911B2 (en) 2002-05-30
WO1999042443A1 (en) 1999-08-26
HUP0101176A3 (en) 2002-06-28
CA2318145C (en) 2009-10-27
EP1918278A1 (en) 2008-05-07
PL342009A1 (en) 2001-05-07
CA2318145A1 (en) 1999-08-26
NZ505968A (en) 2003-03-28
AU2923599A (en) 1999-09-06
EP1053226A1 (en) 2000-11-22
US6277987B1 (en) 2001-08-21
IL137465A0 (en) 2001-07-24
KR20010040698A (ko) 2001-05-15
JP2002503720A (ja) 2002-02-05
ID24957A (id) 2000-08-31
NO317977B1 (no) 2005-01-17
RU2208609C2 (ru) 2003-07-20
NO20003565L (no) 2000-10-03
NO20003565D0 (no) 2000-07-11
HUP0101176A2 (hu) 2001-09-28
TR200002224T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
BR9909322A (pt) Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz
EA200100230A1 (ru) Производные 1h-имидазопиридина
RU2002125860A (ru) Новые производные циклического амида
ATE106245T1 (de) Anwendung von monoaminakridinen bei mangelerscheinungen des cholinergen nervensystems.
NZ240676A (en) Heterocyclic compounds substituted by a (piperidin-4-yl)-1-oxoalkyl group and pharmaceutical compositions thereof
DE69433148D1 (de) Tricyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
RO93855A (ro) Procedeu pentru prepararea de arilciclobutilalchilamina
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
DE69022058D1 (de) 1-Aryl-1-hydroxy-1-substituierte-3-(4-substituierte-1-piperazinyl)-2-propanone und ihre Verwendung bei der Behandlung von Blasenstörungen neurologischen Ursprungs.
DE69329084D1 (de) Benzoxazepin-Derivate als Cholinesterase-Inhibitoren
KR880009957A (ko) 알킬-치환된 n-벤조피라닐락탐, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제
DE69011781D1 (de) 1-acyl-2-pyrrolidinone zur Verbesserung der Lernfähigkeit und des Gedächtnisses und diese enthaltende pharmazeutische Zubereitungen.
ATE8389T1 (de) Amino-alkoxy-pyrazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE293628T1 (de) Dihydrobenzofuranderivate, verfahren zu ihrer herstellung und mittel
NO984547L (no) Nye oksazolidinderivater, fremgangsmÕte for deres fremstilling, samt legemidler inneholdende disse forbindelser
ES454285A1 (es) Procedimiento para preparar derivados de 4-amina trans-deca-hidroquinolina.
DK99588A (da) 2-(aminoalkythio)methyl-1,4-dihydropyridin-forbindelser, en fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
TH25787A (th) เอสเทอร์และแอมีดของได-ซับสทิทิวเทด 1,4-พิเพอริดีน
TH13838EX (th) สิ่งเคลือบบนกระจก
RU99115884A (ru) Пролекарственные формы и новые аналоги камптотецина, их применение в качестве лекарственных средств
TH8799EX (th) การใช้อนุพันธ์ของอิมิแดโซพิแรโซลเป็นสารแก้ปวดและต่อต้านการอักเสบ
TH9548B (th) &#34;การใช้ประโยชน์ของอนุพันธ์ของลิกแนนสำหรับการเตรียมสารผสมทางเภสัชสำหรับการบำบัดรักษาสถานะของการพอกจับตัวของแอมิลอยด์&#34;
TH7138A (th) ไฮดราไซด์ และอนุพันธ์กรดไฮดรอกซามิค
BR9908057A (pt) Derivados de amino antraciclinona
TH51750A (th) อนุพันธ์โครแมนที่ถูกแทนที่

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.